Prevymis (letermovir) - Merck (MSD)
Clinical study on the use of letermovir for the prevention of cytomegalovirus infection in Chinese kidney transplant recipients (ChiCTR) - Aug 7, 2025 - P4 | N=100 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University 
New P4 trial • Cytomegalovirus Infection • Infectious Disease • Transplantation
https://www.chictr.org.cn/showproj.html?proj=281754
 
Aug 7, 2025
 
Prev Next